Growing evidence indicates that tau pathology can also exert synergistic effects with amyloid peptide and that it correlates more closely to the progression and cognitive impairment of AD than Aβ plaques (Bejanin et al., 2017; Guo et al., 2020). The gene discussed is MAPT; the disease is Cognitive impairment.